ETON — Eton Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- $89.92m
- $78.28m
- $31.64m
- 65
- 24
- 34
- 36
2019 December 31st | 2020 December 31st | C2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.959 | 0.039 | 21.8 | 21.3 | 31.6 |
Cost of Revenue | |||||
Gross Profit | 0.506 | -0.247 | 19 | 14.3 | 21.1 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 19.6 | 27.1 | 23 | 29.5 | 32.8 |
Operating Profit | -18.6 | -27.1 | -1.13 | -8.26 | -1.19 |
Total Net Non Operating Interest Income / Expense | |||||
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -18.3 | -28 | -1.96 | -9.02 | -0.689 |
Provision for Income Taxes | |||||
Net Income After Taxes | -18.3 | -28 | -1.96 | -9.02 | -0.936 |
Net Income Before Extraordinary Items | |||||
Net Income | -18.3 | -28 | -1.96 | -9.02 | -0.936 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -18.3 | -28 | -1.96 | -9.02 | -0.936 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.03 | -1.33 | -0.099 | -0.359 | -0.036 |